多系统缩:病理生理学,诊断和治疗方面的进展
Florian Krismer1, Alessandra Fanciulli1, Wassilios G Meissner2
1Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.
The Lancet. Neurology
|November 22, 2024
概括
多种系统缩 (MSA) 是一种进展性神经退行性疾病,具有多种症状. 了解MSA病理生理学的最新进展和修订的诊断标准旨在更早,更准确地诊断和潜在的治疗方法.
科学领域:
- 神经退行性疾病的神经退行性疾病
- 运动障碍 运动障碍
- 神经病理学神经病理学
背景情况:
- 多重系统缩 (MSA) 是一种罕见的,零星的,成人发作的神经退行性疾病.
- 患有广泛的运动和非运动症状的患者.
- 临床重叠与帕金森病和渐进的超核性麻复杂的诊断.
研究的目的:
- 总结一下了解多系统性缩 (MSA) 病理生理学的最新进展.
- 要突出诊断标准的修订,以提高准确性.
- 讨论早期诊断和疾病修饰疗法的潜力.
主要方法:
- 关于MSA病理生理学的最新研究的综述,重点是α-synuclein.
- 对MSA的2022年修订诊断标准的分析.
- 对潜在疗法的当前临床试验数据的评估.
主要成果:
- 了解MSA中的α-synuclein播种和菌株检测的进展.
- 修订后的2022年标准旨在提高诊断准确性,特别是在早期阶段.
- 早期临床试验信号表明疾病修饰疗法的潜力,但神经保护尚未被证明.
结论:
- 了解MSA病理生理学的进步对于生物标志物发现至关重要.
- 改进的诊断标准可以促进早期检测多系统性缩.
- 需要进一步的研究来开发有效的,神经保护性治疗MSA.
相关概念视频
Parkinson's Disease: Overview
482
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
482
Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
Parkinson's Disease: Treatment
220
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
220
Myasthenia Gravis: Diagnostic Tests
653
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
653


